Újonnan kifejlesztett, klasszikus sertéspestis elleni markervakcina regisztrációs hatékonysági vizsgálata

Background: Classical swine fever (CSF) or HOG cholera is a highly contagious and devastating disease of Suidae caused by an enveloped single-stranded RNA virus (CSFV) of the family Flaviviridae, genus Pestivirus. CSF has vast economic and trade significance all over the worldi and it has the massive potential to spread rapidly from country to country. This is the reason why the World Organisation for Animal Health has listed CSF as a Notifiable Disease and it is also considered a transboundary animal disease. Objective: The objective of the present studies was to determine the efficacy of a single dose of a newly developed marker vaccine candidate against CSF, administered intramuscularly or orally in 6-week-old domestic piglets with and without maternally derived antibodies (MDAs) against Pestiviruses, to provide protection against a challenge with the highly virulent CSFV strain "Koslov" 14 days post vaccination. Materials and Methods: In both experiments two test groups were formed with 15 animals each, one group for intramuscular (im.), while another one for oral (p.o.) immunisation. The control groups contained 10 animals as unvaccinated controls, respectively. All piglets were oronasally challenged with the highly virulent CSF virus (CSFV) strain "Koslov" 14 days post-vaccination. Results and Discussion: The vaccine candidate when administered im. provided complete protection in MDA- animals, while p.o. administration triggered only partial protection. Furthermore, we found that the presence of the MDAs had negative effect on the efficacy of the vaccine candidate. However, this was greatly influenced by the route of administration. Based on our observations, im. administration is recommended to achieve better immune response during the CSF control programs. The vaccine candidate met the criteria of Ph. Eur Monograph 0065, "Swine-fever vaccine (live, prepared in cell cultures), classical" 7th Edition. Fulfilling these validity criteria is a key step in the registration procedure for a vaccine candidate. © 2019 Herman Otto Intezet. All rights reserved.

A szerzők klasszikus sertéspestis (KSP) ellen újonnan kifejlesztett markervakcina hatékonyságát vizsgálták fertőzéses kísérletekben hathetes malacokon. Az oltatlan kontroll csoportokkal ellentétben a kezelt csoportokat izomba oltva (im.), vagy szájon át (p.o.) immunizálták. A vakcinázást követő 14. napon a malacokat oronasalisan fertőzték virulens KSP-vírustörzzsel. Az im. alkalmazott vakcina a kezelt állatokban megfelelő védettséget biztosított, míg a p.o. alkalmazás csak részleges védelmet nyújtott. Megállapították továbbá, hogy az anyai ellenanyagok jelenléte károsan befolyásolta a vakcinajelölt hatékonyságát, ami azonban nagymértékben függött az alkalmazás módjától.

Dateien

Zitieren

Zitierform:
Zitierform konnte nicht geladen werden.

Zugriffsstatistik

Gesamt:
Volltextzugriffe:
Metadatenansicht:
12 Monate:
Volltextzugriffe:
Metadatenansicht:

Rechte

Nutzung und Vervielfältigung:
Alle Rechte vorbehalten